[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Fragile X Syndrome - Pipeline Review, H2 2019

November 2019 | 172 pages | ID: FC04677E930EN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Fragile X Syndrome - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome - Pipeline Review, H2 2019, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape.

Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Fragile X syndrome is caused by a change in a gene called FMR1. Fragile X syndrome occurs both in male and female. Symptoms include delay in crawling, walking, or twisting, hyperactive or impulsive behavior, speech and language delay and intellectual disability.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fragile X Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 2 and 17 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fragile X Syndrome (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fragile X Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fragile X Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fragile X Syndrome (Genetic Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fragile X Syndrome (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fragile X Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Fragile X Syndrome - Overview
Fragile X Syndrome - Therapeutics Development
Fragile X Syndrome - Therapeutics Assessment
Fragile X Syndrome - Companies Involved in Therapeutics Development
Fragile X Syndrome - Drug Profiles
Fragile X Syndrome - Dormant Projects
Fragile X Syndrome - Discontinued Products
Fragile X Syndrome - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Fragile X Syndrome, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Fragile X Syndrome - Pipeline by Advanced Medical Projects, H2 2019
Fragile X Syndrome - Pipeline by Anavex Life Sciences Corp, H2 2019
Fragile X Syndrome - Pipeline by Autifony Therapeutics Ltd, H2 2019
Fragile X Syndrome - Pipeline by Confluence Pharmaceuticals LLC, H2 2019
Fragile X Syndrome - Pipeline by DRI Biosciences Corp, H2 2019
Fragile X Syndrome - Pipeline by Epigen Biosciences Inc, H2 2019
Fragile X Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2019
Fragile X Syndrome - Pipeline by GW Pharmaceuticals Plc, H2 2019
Fragile X Syndrome - Pipeline by Healx Ltd, H2 2019
Fragile X Syndrome - Pipeline by Lysogene SAS, H2 2019
Fragile X Syndrome - Pipeline by Marinus Pharmaceuticals Inc, H2 2019
Fragile X Syndrome - Pipeline by Neuren Pharmaceuticals Ltd, H2 2019
Fragile X Syndrome - Pipeline by Neuron Biopharma SA, H2 2019
Fragile X Syndrome - Pipeline by Neurotrope Bioscience Inc, H2 2019
Fragile X Syndrome - Pipeline by Novartis AG, H2 2019
Fragile X Syndrome - Pipeline by Ovid Therapeutics Inc, H2 2019
Fragile X Syndrome - Pipeline by Prous Institute for Biomedical Research SA, H2 2019
Fragile X Syndrome - Pipeline by Sage Therapeutics Inc, H2 2019
Fragile X Syndrome - Pipeline by Sentinel Oncology Ltd, H2 2019
Fragile X Syndrome - Pipeline by Seropeutics LLC, H2 2019
Fragile X Syndrome - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Fragile X Syndrome - Pipeline by Tetra Therapeutics, H2 2019
Fragile X Syndrome - Pipeline by Zynerba Pharmaceuticals Inc, H2 2019
Fragile X Syndrome - Dormant Projects, H2 2019
Fragile X Syndrome - Dormant Projects, H2 2019 (Contd..1), H2 2019
Fragile X Syndrome - Discontinued Products, H2 2019

LIST OF FIGURES

Number of Products under Development for Fragile X Syndrome, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Advanced Medical Projects
Anavex Life Sciences Corp
Autifony Therapeutics Ltd
Confluence Pharmaceuticals LLC
DRI Biosciences Corp
Epigen Biosciences Inc
GlaxoSmithKline Plc
GW Pharmaceuticals Plc
Healx Ltd
Lysogene SAS
Marinus Pharmaceuticals Inc
Neuren Pharmaceuticals Ltd
Neuron Biopharma SA
Neurotrope Bioscience Inc
Novartis AG
Ovid Therapeutics Inc
Prous Institute for Biomedical Research SA
Sage Therapeutics Inc
Sentinel Oncology Ltd
Seropeutics LLC
Takeda Pharmaceutical Co Ltd
Tetra Therapeutics
Zynerba Pharmaceuticals Inc


More Publications